Therapeutic success of rifaximin for Clostridium difficile infection refractory to metronidazole and vancomycin

Case Reports in Gastroenterology

Volumn 4, Issue 3, 2010, Pages 404-409

  Tannous, George ^a   Neff, Guy ^a,b   Kemmer, Nyingi ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b LifeLink Foundation   (United States)

Author keywords

Metronidazole; Recurrent Clostridium difficile infection; Rifaximin; Saccharomyces boulardii; Vancomycin

Indexed keywords

METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; VANCOMYCIN;

ADULT; ARTICLE; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; FECES ANALYSIS; HUMAN; MALE; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; SIGMOIDOSCOPY; SYMPTOM; TREATMENT DURATION;

EID: 78751491670     PISSN: None     EISSN: 16620631     Source Type: Journal    
DOI: 10.1159/000320685     Document Type: Article

References (15)

1. Calfee DP: Clostridium difficile: A reemerging pathogen. Geriatrics 2008;63:10-21.
2. Owens RC: Clostridium difficile-associated disease: Changing epidemiology and implications for management. Drugs 2007;67:487-502.
3. Jodlowski TZ, Oehler R, Kam LW, Melnychuk I: Emerging therapies in the treatment of Clostridium difficileassociated disease. Ann Pharmacother 2006;40:2164-2169.
4. McFarland LV: Alternative treatments for Clostridium difficile disease: What really works? J Med Microbiol 2005;54:101-111.
5. Scarpignato C, Pelosini I: Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(suppl 1):13-27.
6. Xifaxan [package insert]. Morrisville, NC, Salix Pharmaceuticals, Inc., 2010.
7. DuPont HL, Jiang ZD: Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004;10:1009-1011.
8. Kokkotou E, Moss AC, Michos A, Espinoza D, Cloud JW, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP: Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother 2008;52:1121-1126.
9. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN: Interruption of recurrent Clostridium difficileassociated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-848.
10. Garey KW, Jiang ZD, Bellard A, DuPont HL: Rifaximin in treatment of recurrent Clostridium difficileassociated diarrhea: An uncontrolled pilot study [letter]. J Clin Gastroenterol 2009;43:91-92.
11. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG: Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: Comparison of two dosage regimens. Am J Med 1989;86:15-19.
12. McFarland LV, Elmer GW, Surawicz CM: Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769-1775.
13. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW: The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-1017.
14. Tedesco FJ, Gordon D, Fortson WC: Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985;80:867-868.
15. Buggy BP, Fekety R, Silva J Jr: Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987;9:155-159.